Crewe Advisors LLC
- SEC CIK
- 0001730033
- Latest filing
- Jul 23, 2026
AZN holding history
AstraZeneca PLC in every 13F filed by Crewe Advisors LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
AZN overviewAll 13F holders of AZNFull Q2 2026 holdings
- Shares (Q2 2026)
- 967
- Value
- $183.4K
- % of portfolio
- <0.1%
- Quarters held
- 16
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 967 | $183.4K | <0.1% | +30+3.2% | Added | Holders |
| Q1 2026 | 937 | $184.8K | <0.1% | −7−0.7% | ReducedConverted for a 1-for-2 split | Holders |
| Q4 2025 | 1,887 | $173.5K | <0.1% | +13+0.7% | Added | Holders |
| Q3 2025 | 1,874 | $143.8K | <0.1% | +1,874 | New | Holders |
| Q3 2024 | 0 | $0 | 0.0% | −2,170−100.0% | Sold out | Holders |
| Q2 2024 | 2,170 | $169.2K | <0.1% | +213+10.9% | Added | Holders |
| Q1 2024 | 1,957 | $132.6K | <0.1% | +1,957 | New | Holders |
| Q3 2023 | 0 | $0 | 0.0% | −1,920−100.0% | Sold out | Holders |
| Q2 2023 | 1,920 | $137.4K | <0.1% | −550−22.3% | Reduced | Holders |
| Q1 2023 | 2,470 | $171.4K | <0.1% | −129−5.0% | Reduced | Holders |
| Q4 2022 | 2,599 | $176.2K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2022 | 2,599 | $143.0K | <0.1% | +175+7.2% | Added | Holders |
| Q2 2022 | 2,424 | $160.0K | <0.1% | +550+29.3% | Added | Holders |
| Q1 2022 | 1,874 | $124.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2021 | 1,874 | $109.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2021 | 1,874 | $113.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2021 | 1,874 | $112.0K | <0.1% | −255−12.0% | Reduced | Holders |
| Q1 2021 | 2,129 | $106.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.